This is a 4-week non-randomized, partially blinded, single-arm monocentre study in subjects
with Chronic Obstructive Pulmonary Disease (COPD) Global Initiative for Chronic Obstructive
Lung Disease (GOLD) class II or III with the aim to demonstrate that inhaled therapy with
salmeterol reduces sympathetic activity as evaluated by microneurography. A maximum of 32
subjects is planned to be enrolled.